Highlights

  • Evogene will attend BIO-Europe in Cologne on November 9–11, 2026.
  • The company will present ChemPass AI at a Barcelona conference on November 10–12.
  • Its chief development officer will meet prospective collaboration partners.
  • ChemPass AI spans virtual screening, hit-to-lead analysis and molecular design.

Evogene Ltd. (NASDAQ:EVGN) is preparing for two European industry gatherings in November, taking its AI-based computational chemistry platform to potential pharmaceutical and biotechnology collaborators. The company will participate in BIO-Europe in Cologne, Germany, and Drug Discovery Chemistry Europe in Barcelona, Spain, with meetings and a scientific poster focused on its small-molecule discovery capabilities.

Cologne Opens the Door to Partner Discussions

BIO-Europe takes place November 9–11, 2026. Evogene Chief Development Officer Dr. Gabi Tarcic will represent the company and be available for individual meetings with prospective partners. The discussions will center on possible collaboration opportunities in AI-driven small-molecule discovery and development. The conference appearance gives Evogene a scheduled opportunity to explain its computational approach directly to organizations exploring drug discovery programs.

Barcelona Showcases the Technology Platform

Drug Discovery Chemistry Europe runs November 10–12, 2026, in Barcelona. A delegation of Evogene executives involved in technology development will attend and present a scientific poster titled “ChemPass AI: An End-to-End Small Molecule Discovery Platform – From Virtual Screening to De Novo Molecular Design.” The poster will describe the platform’s capabilities and provide a basis for conversations with industry colleagues about strategic technology collaborations.

ChemPass AI Covers Multiple Discovery Stages

ChemPass AI combines proprietary AI tools for virtual screening, quantitative structure–activity relationship-driven hit-to-lead work and advanced generative de novo molecular design. These functions are intended to support discovery and optimization of novel small molecules. Evogene describes its platform as a way to explore extensive chemical space while optimizing candidate molecules across several important parameters. The company applies this technology in pharmaceutical and agricultural product development, working through partnerships and internal programs.

November Meetings Define the Immediate Agenda

The two events overlap by two days, placing partner meetings in Germany alongside a technical presentation in Spain. Evogene has invited pharmaceutical and biotechnology companies interested in collaborative discovery programs to make contact. Its announced activities are conference participation, discussions and a poster presentation; the release does not announce a new partnership or commercial agreement. The next scheduled milestones are the November conference dates and the planned engagements around ChemPass AI.